Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antipsychotic drug has few side effects in Alzheimer’s patients

19.09.2002


A drug used to help control psychotic behavior in people with schizophrenia holds promise for controlling similar symptoms in the early stages of Alzheimer’s disease, a new study suggests.

What sets this drug – called quetiapine – apart from its contemporary counterparts is its apparent lack of serious side effects, such as confusion, muscle stiffness and imbalance in the joints, said Douglas Scharre, a study co-author and an associate professor of clinical neurology at Ohio State University.

None of the 10 subjects in the study reported any of these symptoms during a 12-week trial.



“Quetiapine should be considered the first line of treatment for psychosis in Alzheimer’s patients because of its lack of serious side effects,” Scharre said, adding that while no antipsychotic medication is currently approved by the Food and Drug Administration to treat Alzheimer’s-related psychosis, physicians can prescribe it as an “off-label” use. An estimated 4 million people in the United States have the disease.

The research appears in a recent issue of the journal Alzheimer Disease and Associated Disorders.

Scharre and co-author Shu-Ing Chang, a clinical instructor of neurology at Ohio State, prescribed quetiapine (brand name Seroquel) to patients with mild to moderate forms of Alzheimer’s disease. Their study is the first to look at the effects quetiapine may have on cognitive function in the disease.

The researchers recruited 10 outpatients with a diagnosis of probable Alzheimer’s disease and who had symptoms of psychotic or aggressive behaviors severe enough to justify drug treatment on a regular basis. Quetiapine was the only antipsychotic medication prescribed during the 12-week study.

The researchers evaluated the subjects at the beginning of the study and again at six and 12 weeks. They measured behavioral symptoms using the Neuropsychiatric Inventory and evaluated cognitive abilities using the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog). The patients also underwent a physical examination at each visit. Subjects were monitored weekly via telephone conversations.

The subjects began the study by taking 25 milligrams of quetiapine each night at bedtime. Dosages were increased by 25 mg weekly if symptoms of aggression and psychosis were still evident.

The average dose of quetiapine at the end of the study was 50 mg twice daily. Dosing ranged from 50 mg to 150 mg per patient per day, a fraction of what is normally required to control psychotic behavior in schizophrenic patients.

“Schizophrenics don’t show much of a response until the dose is 150 mg or higher, and may require up to 600 to 800 mg of quetiapine to ease psychotic symptoms,” Scharre said.

At the end of the current study, quetiapine at the 50 to 150 mg level did not significantly worsen cognitive function in the Alzheimer’s subjects. In fact, the average ADAS-cog scores improved slightly after six weeks.

“The decrease in aggression and psychotic behavior at this point may also have contributed to the improvement in cognitive scores,” Scharre said.

However, at week 12 the cognitive scores decreased slightly from what they were at the outset of the study. This most likely represents the natural result of the disease progression, and not the use of quetiapine, Scharre said.

The average Alzheimer’s patient in the early to middle stages of the disease will usually show a decrease in cognition of five to 11 points annually on the ADAS-cog scale, or about one to three points every three months. The cognition of the subjects in the current study decreased an average of 2.4 points during the 12-week study.

As for physical side effects induced by quetiapine, four out of the 10 patients in the current study reported feeling drowsy at times, but the side effect was temporary. Four of the 10 patients also gained an average of four pounds while taking the drug, which might be a welcome side effect as weight loss is a common problem in Alzheimer’s patients.

The subjects didn’t report feeling dizzy nor did they complain of stiff joints or muscles. That’s important, Scharre said, as people with the disease are elderly and prone to falling.

“While many of the currently available medications work well in controlling psychosis, they can cause confusion or Parkinson’s disease-like symptoms, such as increased stiffness and tremor.”

While he uses quetiapine to help control psychotic behavior in patients at all stages of the disease, Scharre said it’s particularly important for patients in the early stages of Alzheimer’s to take medications – such as quetiapine – that don’t increase cognitive loss.

“A physician hopes to help patients retain as much cognitive function as possible, in a disease where cognitive decline is the norm,” he said.


Contact: Douglas Scharre, 614-293-8531; Scharre.1@osu.edu
Written by Holly Wagner, 614-292-8310; Wagner.235@osu.edu

Douglas Scharre | EurekAlert!

More articles from Health and Medicine:

nachricht Study shows novel protein plays role in bacterial vaginosis
13.12.2019 | University of Arizona Health Sciences

nachricht Illinois team develops first of a kind in-vitro 3D neural tissue model
12.12.2019 | University of Illinois College of Engineering

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Virus multiplication in 3D

Vaccinia viruses serve as a vaccine against human smallpox and as the basis of new cancer therapies. Two studies now provide fascinating insights into their unusual propagation strategy at the atomic level.

For viruses to multiply, they usually need the support of the cells they infect. In many cases, only in their host’s nucleus can they find the machines,...

Im Focus: Cheers! Maxwell's electromagnetism extended to smaller scales

More than one hundred and fifty years have passed since the publication of James Clerk Maxwell's "A Dynamical Theory of the Electromagnetic Field" (1865). What would our lives be without this publication?

It is difficult to imagine, as this treatise revolutionized our fundamental understanding of electric fields, magnetic fields, and light. The twenty original...

Im Focus: Highly charged ion paves the way towards new physics

In a joint experimental and theoretical work performed at the Heidelberg Max Planck Institute for Nuclear Physics, an international team of physicists detected for the first time an orbital crossing in the highly charged ion Pr⁹⁺. Optical spectra were recorded employing an electron beam ion trap and analysed with the aid of atomic structure calculations. A proposed nHz-wide transition has been identified and its energy was determined with high precision. Theory predicts a very high sensitivity to new physics and extremely low susceptibility to external perturbations for this “clock line” making it a unique candidate for proposed precision studies.

Laser spectroscopy of neutral atoms and singly charged ions has reached astonishing precision by merit of a chain of technological advances during the past...

Im Focus: Ultrafast stimulated emission microscopy of single nanocrystals in Science

The ability to investigate the dynamics of single particle at the nano-scale and femtosecond level remained an unfathomed dream for years. It was not until the dawn of the 21st century that nanotechnology and femtoscience gradually merged together and the first ultrafast microscopy of individual quantum dots (QDs) and molecules was accomplished.

Ultrafast microscopy studies entirely rely on detecting nanoparticles or single molecules with luminescence techniques, which require efficient emitters to...

Im Focus: How to induce magnetism in graphene

Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.

Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties – for example,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The Future of Work

03.12.2019 | Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

 
Latest News

Supporting structures of wind turbines contribute to wind farm blockage effect

13.12.2019 | Physics and Astronomy

Chinese team makes nanoscopy breakthrough

13.12.2019 | Physics and Astronomy

Tiny quantum sensors watch materials transform under pressure

13.12.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>